SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-187257
Filing Date
2023-07-14
Accepted
2023-07-14 16:05:57
Documents
13
Period of Report
2023-07-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d489147d8k.htm   iXBRL 8-K 27132
  Complete submission text file 0001193125-23-187257.txt   184203

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20230713.xsd EX-101.SCH 3217
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20230713_def.xml EX-101.DEF 13746
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230713_lab.xml EX-101.LAB 22638
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230713_pre.xml EX-101.PRE 14562
7 EXTRACTED XBRL INSTANCE DOCUMENT d489147d8k_htm.xml XML 5098
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231089176
SIC: 2834 Pharmaceutical Preparations